{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=28232", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=28232", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=28232&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=28232&_page=0", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=28232", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=28232", "items" : [{"_about" : "http://data.parliament.uk/resources/1344069", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1344069/answer", "answerText" : {"_value" : "

The Medicines and Healthcare products Regulatory Agency (MHRA) is conducting a review of topical steroid withdrawal. The review is discussing alterations to labelling, guidance and communications with health care professionals. We have consulted on these topics with healthcare experts in the field including those in the National Health Service, patient representatives and other stakeholders. We are considering updates to the product information and further communications to health care professionals and the MHRA expects to issue more information on this in the next few months.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} , "dateOfAnswer" : {"_value" : "2021-07-28", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "28230"} , {"_value" : "28231"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-07-28T12:13:02.65Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-07-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Steroid Drugs: Labelling"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department plans to modify the labelling of topical steroid medications to include clear warnings against over-use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"} } , "tablingMemberConstituency" : {"_value" : "Bristol West"} , "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"} ], "uin" : "28232"} , {"_about" : "http://data.parliament.uk/resources/454866", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/454866/answer", "answerText" : {"_value" : "

National immunisation programmes are introduced on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), the independent expert body that advises the Government on all immunisation matters. JCVI\u2019s recommendations are based on a comprehensive and careful review of a wide range of evidence including information from medical experts.<\/p>

<\/p>

JCVI reviewed the available evidence on meningitis B vaccine and recommended a national Meningococcal B (MenB) immunisation programme for infants. The MenB vaccine is first offered to babies at 2 months of age, with further doses offered when they reach 4 and 12 months of age.<\/p>

<\/p>

MenB was introduced into the NHS programme in September 2015. JCVI keeps the eligibility criteria of all vaccination programmes under review and considers new evidence as it becomes available. If JCVI provides further advice about the programme, we will consider this.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"} } , "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} , "dateOfAnswer" : {"_value" : "2016-02-29", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "28230"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-02-29T18:21:57.777Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2016-02-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Meningitis: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, when his Department last consulted medical authorities on the potential merits of making the meningitis B vaccine available on the NHS for all children; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/316", "label" : {"_value" : "Biography information for Mr David Winnick"} } , "tablingMemberConstituency" : {"_value" : "Walsall North"} , "tablingMemberPrinted" : [{"_value" : "Mr David Winnick"} ], "uin" : "28232"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }